KPN reports on progress of € 250m share buyback KPN has repurchased 4,755,000 KPN ordinary shares in the period from 21 April to 25 April 2025. The shares were repurchased at an average price of € 3.99 per share for a total consideration of € 19.0m. These repurchases are part of the € 250m share buyback started on 25 February 2025 and reflect KPN's commitment to structurally return additional capital to its shareholders. The total number of ordinary shares repurchased to date is 19,089,964 for a total consideration of € 73.6m. Transaction details of the share buyback are available on our ...
JDE Peet’s share buyback periodic update April 28, 2025 PRESS RELEASE Amsterdam, April 28, 2025 JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee and tea company, today announced that it has repurchased 34,549 shares in the period from April 21, 2025 up to and including April 25, 2025. The shares were repurchased at an average price of EUR 20.88 per share for a total consideration of EUR 0.7 million. These repurchases were made as part of the EUR 250 million share buyback programme . The total number of shares repurchased under this programme to date is 3,556,163 ordina...
Heineken N.V. reports the progress of transactions under its current share buyback programme Heineken N.V. reports the progress of transactions under its current share buyback programme Amsterdam, 28 April 2025 - Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the first €750 million tranche of its €1.5 billion share buyback programme as communicated on 12 February 2025. From 21 April 2025 up to and including 25 April 2025 a total of 41,891 shares were repurchased on exchange at an average price of € 77.79. During the same period, 28,004 shar...
Last Friday evening, Autolus announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation for Aucatzyl (CD19 CAR-T) in adult relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), in line with the expected timeline. Looking ahead, Autolus will report its 1Q25 results on 8 May, where the first quarter US sales of Aucatzyl will be reported and will give us a quantitative view on the launch momentum – note that ...
Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1) UK Medicines and Healthcare products Regulatory Agency (MHRA) authorisation based on FELIX clinical trial of obecabtagene autoleucel in adult patients with r/r B-ALL1AUCATZYL® licensed from MHRA under ‘conditional marketing authorisation’, meaning that the MHRA will review new efficacy and safety information at least once every year1 Investors, US and UK National, Medical and ...
Umicore issued an unexpected (qualitative) trading update in which it also reiterated its FY25 adjusted EBITDA guidance range of € 720-780m. Given the uncertain economic outlook, we decided to lower our forecast by 3% to € 734m, closer to the bottom end of the guidance range. We remind that Umicore recently organized a CMD, expressing the ambition to try to monetize past investments in Battery Materials, acknowledging that some additional capex and equity investment into the Ionway JV are still ...
Allfunds Group plc: 1Q25 Preview. Azelis: 1Q25 EBITA miss on tariff uncertainty, €20m self-help to support margins. Exor: Announces oversubscribed €1bn SBB tender offer, strike at VWAP +2%. Flow Traders: Mike drop. Fugro: 1Q25 as expected but outlook a question mark. IMCD: Breaking with tradition: CEO gone within 15 months. Kinepolis: Weak 1Q25, offset by a strong 2Q25 start. KPN: Small 1Q25 EBITDAal beat, guidance reiterated. Randstad: Capital Markets Event. RELX: 1Q25 trading...
KPN reported a solid set of 1Q25 results, with adj. service revenues up 3.1% organically to € 1319m, hereby slightly exceeding expectations (kbcse: € 1310m, css: € 1311m). Adj. EBITDAal increased 3.1% organically to € 634m, or comfortably above expectations (kbcse & € 624m). The group also reiterated its upward revised guidance from mid-February. Following the recent share price rally due to KPN's limited direct impact to tariffs, we lower our rating from Buy to Hold and reiterate our € 4.2 TP.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.